KEQU
Kewaunee Scientific Corporation
KEQU has lower modeled downside risk, despite its lower overall score.
LCID
Lucid Group, Inc.
LCID has the edge over KEQU overall, supported by stronger valuation and stronger fundamentals.
KEQU Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Strong |
KEQU's balance sheet is currently strong, and its revenue and profitability are stable, but its cash flow is under pressure.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
KEQU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.5x | $20.79 | -42% |
| Fair | 11x | $29.03 | -19% |
| Expensive | 13x | $36.49 | +1.5% |
| Current | 13x | $35.94 | — |
Historical ranges are pointers, not guarantees.
KEQU's PE is in its expensive range at 13x.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
KEQU Forward outlook
There aren't enough analyst estimates for KEQU to show an outlook.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
KEQU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.76 | -33% |
| Q2 2026 | $3.22 | -16% |
| Q1 2026 | $3.72 | -37% |
| Q4 2025 | $3.94 | -38% |
| Q3 2025 | $4.13 | -34% |
| Q2 2025 | $3.83 | -40% |
| Q1 2025 | $5.94 | +98% |
| Q4 2024 | $6.34 | +164% |
KEQU has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
KEQU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $66.3M | -6.7% |
| Q2 2026 | $71.4M | -7.5% |
| Q1 2026 | $69.4M | +3.3% |
| Q4 2025 | $70.1M | +47% |
| Q3 2025 | $71.1M | +47% |
| Q2 2025 | $77.1M | +36% |
| Q1 2025 | $67.2M | +44% |
| Q4 2024 | $47.8M | -5.3% |
KEQU's revenue is growing: $66M last quarter, down 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.8% | -2 points |
| Q2 2026 | 7.3% | -3.7 points |
| Q1 2026 | 3.7% | +0.4 points |
| Q4 2025 | 5.9% | -3.4 points |
| Q3 2025 | 6.8% | +1.4 points |
| Q2 2025 | 11% | +1.2 points |
| Q1 2025 | 3.4% | -4.8 points |
| Q4 2024 | 9.3% | -0.9 points |
KEQU has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over KEQU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
KEQU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -76% |
| Q2 2026 | $4.5M | -49% |
| Q1 2026 | $11M | +$13.9M |
| Q4 2025 | -$5.8M | -175% |
| Q3 2025 | $5M | +$6.1M |
| Q2 2025 | $8.9M | +5256% |
| Q1 2025 | -$3M | -133% |
| Q4 2024 | $7.8M | +$8.3M |
KEQU has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
KEQU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -62K shares |
| 1 year | -1.4% | -42K shares |
| 3 years | +1.2% | +36K shares |
| 5 years | +5.2% | +144K shares |
| Available history | +6.2% | +171K shares |
KEQU has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $529,000 |
| Q2 2025 | $1.6M |
| Q2 2024 | $1.2M |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
KEQU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.5x | Healthy |
| Q4 2024 | -1.3x | Net Cash |
KEQU's net debt is less than a year of its operating earnings (EBITDA).
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KEQU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 35.7 | Neutral |
KEQU's weekly RSI is 51 (neutral) and its Stochastic is 36 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
KEQU PE vs Consumer Cyclical Sector
| Metric | KEQU | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 18x | 28% below |
| PE % | 81 | 47 | 34 pts above |
KEQU is trading at 13x earnings, a 28% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
KEQU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.9 | 6% above |
| 20 week MA | $35.4 | 1.5% above |
| 50 week MA | $37.0 | 2.9% below |
| 100 week MA | $42.5 | 15% below |
| 200 week MA | $35.1 | 2.4% above |
KEQU has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
KEQU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.1 | $10.6 | -19% |
| 2021 | $10.6 | $12.3 | +16% |
| 2022 | $12.3 | $15.8 | +28% |
| 2023 | $15.8 | $29.1 | +85% |
| 2024 | $29.1 | $63.8 | +120% |
| 2025 | $63.8 | $38.0 | -40% |
| 2026 YTD | $38.0 | $35.9 | -5.4% |
KEQU has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.